{"nctId":"NCT02245672","briefTitle":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","startDateStruct":{"date":"2014-10"},"conditions":["Asthma"],"count":1128,"armGroups":[{"label":"MGR001","type":"EXPERIMENTAL","interventionNames":["Drug: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)"]},{"label":"Advair Diskus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)","otherNames":[]},{"name":"Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key inclusion criteria include:\n\n* Male or female subjects aged ≥18 years. Females may be of either childbearing or non-childbearing potential\n* Physician diagnosed history of asthma for at least 12 weeks prior to screening\n* pre-bronchodilator FEV1 60-85% at screening and other specified visits\n* Post-bronchodilator reversibility \\>/=12%\n* Non-smokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of ≤10 pack-years\n* Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required\n* Body mass index between 18-40 kg/m2 inclusive\n\nKey exclusion criteria include:\n\n* Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities\n* Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, Churg-Strauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis\n* History of life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s)\n* In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period\n* An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening\n* History of seasonally unstable asthma where the season will coincide with the subject's participation in the study\n* Use of prescription or non-prescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc\n* Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy\n* Clinically significant abnormalities in the screening ECG\n* Evidence of alcohol or drug abuse or dependency within 6 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity)","description":"The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9534","spread":"0.1609"},{"groupId":"OG001","value":"3.4964","spread":"0.1595"},{"groupId":"OG002","value":"0.8191","spread":"0.3477"}]}]}]},{"type":"PRIMARY","title":"Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Bioequivalence)","description":"The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9734","spread":"0.1704"},{"groupId":"OG001","value":"3.5411","spread":"0.1593"},{"groupId":"OG002","value":"0.8400","spread":"0.2983"}]}]}]},{"type":"PRIMARY","title":"FEV1 Trough Value (Assay Sensitivity)","description":"Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2927","spread":"0.0162"},{"groupId":"OG001","value":"0.2720","spread":"0.0161"},{"groupId":"OG002","value":"0.0575","spread":"0.0353"}]}]}]},{"type":"PRIMARY","title":"FEV1 Trough Value (Bioequivalence)","description":"Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2911","spread":"0.0163"},{"groupId":"OG001","value":"0.2728","spread":"0.0162"},{"groupId":"OG002","value":"0.0574","spread":"0.0355"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":512},"commonTop":["Asthma","Upper respiratory tract infection","Nasopharyngitis","Oropharyngeal pain","Headache"]}}}